Peter Mac scientists are working with the CSIRO to advance a potential new drug that could boost the body’s defenses against a range of cancers.

Their target is a protein known to drive prostate cancer and also those caused by Human Papillomavirus (HPV) including cervical and anal cancers, and cancers of the head and neck.

“HPV is a major cause of cancers of the inner surfaces of the body and irrespective of where these cancers occur, they share the E6AP protein as a common driver,” explains Prof Ygal Haupt of the Tumour Suppression Laboratory at Peter Mac.

“We’ve developed a way to block this cancer-promoting protein and we expect this approach could be effective in developing treatments for HPV-related cancers plus some non-HPV-related cancers, in particular prostate cancer, which also rely on E6AP as a driver.”  

CSIRO and Peter Mac are working through start-up company Vittail on developing novel E6AP inhibiting drugs, based on Prof Haupt’s pioneering research.

Read more about this important work here: